Immunotherapy for advanced or recurrent hepatocellular carcinoma

Table 2 Activity of combinations of immune checkpoint inhibitors from the clinical trials

Drugs	Targets	Other treatment	Trial identifier	Patient group	n	mOS in mo	ORR, %	DCR, %	mPFS in mo	Phase	Setting
Nivolumab + ipilimumab	PD-1; CTLA-4	No	NCT01658878	Advanced HCC	50	22.80	32.0	54.0		I/II	1L
Durvalumab + tremelimumab	PD-L1; CTLA4	vs Durvalumab and tremelimumab	NCT02519348	Unresectable HCC	75	18.70	24.0	45.3	2.17	I/II	2L
Durvalumab + tremelimumab	PD-L1; CTLA4	vs Durvalumab and sorafenib	NCT03298451	Unresectable HCC	393	16.40	20.1	60.1	3.78	III	1L

1L: First-line therapy; 2L: Second-line therapy; CTLA-4: Cytotoxic T lymphocyte-associated antigen 4; DCR: Disease control rate; HCC: Hepatocellular carcinoma; mOS: Median overall survival; mPFS: Median progression free survival; ORR: Overall response rate; PD-1: Programmed cell death protein 1; PD-L1: Programmed death ligand 1.